The estimated Net Worth of Brian Rosenberger is at least $345 Tausend dollars as of 12 September 2023. Mr. Rosenberger owns over 6,411 units of Zynerba Pharmaceuticals Inc stock worth over $324,427 and over the last 8 years he sold ZYNE stock worth over $20,842. In addition, he makes $0 as Vice President - Commercial and Business Development at Zynerba Pharmaceuticals Inc.
Brian has made over 3 trades of the Zynerba Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 6,411 units of ZYNE stock worth $8,527 on 12 September 2023.
The largest trade he's ever made was selling 12,663 units of Zynerba Pharmaceuticals Inc stock on 23 January 2023 worth over $7,598. On average, Brian trades about 1,947 units every 35 days since 2017. As of 12 September 2023 he still owns at least 249,559 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Mr. Rosenberger stock trades at the bottom of the page.
Brian Rosenberger serves as Vice President - Commercial and Business Development of the Company. Over his 25-year career in the pharmaceutical industry, Mr. Rosenberger has held several leadership roles in marketing, sales, business development analytics and alliance management. Prior to joining our company, he was vice president, alliance & strategic portfolio management at Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, from May 2015 to January 2017, where he managed the company's global portfolio. From 2008 to April 2015, Mr. Rosenberger also held various roles of increasing responsibility at Auxilium, a specialty biopharmaceutical company. In his last role as executive director, corporate development & licensing and alliance management he participated in several transformational M&A, licensing and co-promotion deals through and including Endo International's acquisition of Auxilium in January 2015. Prior to joining Auxilium, Mr. Rosenberger held sales managerial positions at Neurocrine Biosciences during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various U.S. and global commercial roles within specialty markets, including neurohealth epilepsy marketing. Mr. Rosenberger holds a B.A. from Dickinson College.
Brian Rosenberger is 51, he's been the Vice President - Commercial and Business Development of Zynerba Pharmaceuticals Inc since 2017. There are 14 older and no younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici und Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include: